Estrogen may facilitate the growth of liver metastases in non-sex-specific cancers
(McGill University Health Centre) A study led by Dr. Pnina Brodt shows that the liver immune microenvironment reacts to metastatic cells differently in male and that in female mice and estrogen can indirectly contribute to the growth of metastases. These findings provide a rationale for further exploration of the role of sex hormones in female cancer patients and the potential benefits of anti-estrogen drugs such as tamoxifen in the treatment of hormone-independent cancers that metastasize to the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2020 Category: International Medicine & Public Health Source Type: news

TP53 Status as Determinant of ESR2 Effects in Breast Cancer TP53 Status as Determinant of ESR2 Effects in Breast Cancer
Therapeutic modification of the mutant TP53-ESR2 interaction with agents such as tamoxifen may offer promise for triple negative breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women
(Queen Mary University of London) The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news

‘No Longer a Disease for Our Moms and Grandmas’: Women on Early Breast Cancer
After a Styles column about one woman ’s experience with an early diagnosis, readers shared poignant stories of fear and survival. (Source: NYT Health)
Source: NYT Health - November 8, 2019 Category: Consumer Health News Authors: Aidan Gardiner Tags: Breast Cancer Mastectomy Radiation Mammography Tamoxifen (Drug) New York Times Source Type: news

Discussing medication therapies that can help prevent breast cancer in high risk patients
The goal of preventive medications is to reduce the risk of developing breast cancer. "The data shows about a 50-60 % reduction in risk," says Dr. Sandhya Pruthi, a Mayo Clinic internal medicine physician and breast cancer expert. Dr. Pruthi's research interests include chemoprevention of breast cancer using selective estrogen receptor modulators, such as tamoxifen [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 3, 2019 Category: Databases & Libraries Source Type: news

New Support for Ovarian Suppression with Endocrine Therapy in Premenopausal Breast Cancer
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Ovarian Suppression Combined with Tamoxifen May Help Premenopausal Patients
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 25, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Update of this US guidance now includes anastrazole as an option in postmenopausal women at increased risk. Tamoxifen 20 mg/day for 5yrs is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 5, 2019 Category: Consumer Health News Source Type: news

Oral lesions and associated factors in breast cancer survivors
First published: 12 August 2019 Abstract AimTo evaluate the prevalence of oral lesions (OL) and associated factors among survivors of breast cancer (BC). MethodsA cross ‐sectional study involving 150 BC survivors was conducted at a public hospital in southern Brazil. Data were collected on socioeconomic aspects, treatment characteristics and oral problems. The decayed, missing and filled teeth index and the occurrence of OL were evaluated. Logistic regression was performed to determine independent variables associated with the outcome. Results24% of the women had at least 1 OL and 33.3% of these had more than o...
Source: Dental Technology Blog - August 14, 2019 Category: Dentistry Source Type: news

Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on  low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1]. (Source: World Pharma News)
Source: World Pharma News - June 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Study: Genetic information can encourage women to accept preventive cancer treatment
CHICAGO ?-- Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventive medicine. A new study by Mayo Clinic and collaborators at [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 3, 2019 Category: Hospital Management Source Type: news

Riskreducing medications for primary breast cancer: a network metaanalysis
This Cochrane Review of 6 studies (n=50,927 on 1 cancer prevention agent (CPA:tamoxifen/raloxifene/exemestane/anastrozole] or placebo) found for women at above ‐average risk of developing breast cancer, CPAs can reduce incidence of this disease. Aromatase inhibitors appear to be more effective. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news

Value of Androgen Receptor Expression in ER+ Breast Cancer Value of Androgen Receptor Expression in ER+ Breast Cancer
Does androgen receptor expression predict response to tamoxifen in women with ER+ breast cancers?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

' Outside the Box': Tamoxifen for Bladder Cancer'Outside the Box': Tamoxifen for Bladder Cancer
Widely used in the treatment of breast cancer because of its estrogen-blocking activity, tamoxifen has now been tested for the first time in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Nolvadex (Tamoxifen Citrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 30, 2019 Category: Drugs & Pharmacology Source Type: news

Promising Strategy Identifies Triple-Negative Breast Cancers That Might Respond to Tamoxifen Promising Strategy Identifies Triple-Negative Breast Cancers That Might Respond to Tamoxifen
Triple-negative breast cancer (TNBC) tumors with estrogen receptor-beta and a mutated p53 tumor suppressor might be responsive to tamoxifen, a series of preclinical studies suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Breast cancer: Reducing this amino acid could make drugs more effective
New research in cell cultures and mice reveals a surprising link between the essential amino acid leucine and resistance to tamoxifen in breast cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Diet high in leucine may fuel breast cancer's drug resistance
(Beth Israel Deaconess Medical Center) A team led by Senthil Muthuswamy, PhD, at the Cancer Center at Beth Israel Deaconess Medical Center, has discovered an unexpected relationship between levels of the amino acid leucine (found in beef, chicken, pork and fish and other foods) and the development of tamoxifen resistance in ER+ breast cancer. These findings reveal a potential new strategy for overcoming resistance to endocrine drugs in ER+ breast cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2019 Category: Cancer & Oncology Source Type: news

Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer
More than six years after a study showed that women with hormone-receptor-positive metastatic breast cancer benefit from a combination of anastrozole and fulvestrant, extended results show the trend has become even more pronounced, but mostly for women not previously exposed to tamoxifen.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 18, 2019 Category: Cancer & Oncology Authors: Charles Shapiro, MD Source Type: news

'Molecular wiring of tumour' predicts breast cancer relapse
New research could lead the way to molecular based treatment and follow-up plans Related items fromOnMedica Thousands of women with breast cancer may be spared chemotherapy Benefit of Herceptin in more breast cancer cases MRI in breast cancer fails to cut reoperation rate Mortality higher if using paroxetine and tamoxifen Physical problems after breast cancer limit survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 14, 2019 Category: UK Health Source Type: news

High Street supplements marketed for heart health and energy could combat infertility
A study by the University of Aberdeen also found that the breast-cancer drug tamoxifen - which blocks oestrogen from fueling a tumour's growth - has a positive effect on a man's swimmers. (Source: the Mail online | Health)
Source: the Mail online | Health - February 14, 2019 Category: Consumer Health News Source Type: news

Risk of Thrombosis Over 2-Fold Higher in Male Breast Cancer With Tamoxifen (CME/CE)
(MedPage Today) -- Increased rate for men consistent with that found in women -- maybe higher (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 12, 2019 Category: Cardiology Source Type: news

Thrombosis a Risk With Tamoxifen in Male Breast Cancer
(MedPage Today) -- Data consistent with findings in women (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2019 Category: Cardiology Source Type: news

USPSTF: Offer Breast Ca Meds to Women at Higher Risk
(MedPage Today) -- But task force says " no " to tamoxifen, raloxifene, or AIs for women at lower risk (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 16, 2019 Category: Hematology Source Type: news

New Tool Calculates Breast Cancer Risk With Greater Precision
(CNN) — UK scientists have developed an online calculator that could enable doctors to more accurately predict a patient’s chance of developing breast cancer. If rolled out, the new tool could change the way in which the condition is treated. Among other things, details of family history, genetics, weight, alcohol consumption, age at menopause and use of hormone replacement therapy will all be considered by doctors when assessing a woman’s risk of developing breast cancer — the most common form of cancer in the UK. Each of these factors has “a small impact on the likelihood of developing the d...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 15, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer CNN Local TV Source Type: news

Clear rub-on gel could cut the risk of breast cancer by starving cells of oestrogen
The clear and odourless gel contains a form of the anti-cancer drug tamoxifen, which has been used for years to treat women with the disease by reducing levels of the hormone oestrogen. (Source: the Mail online | Health)
Source: the Mail online | Health - January 8, 2019 Category: Consumer Health News Source Type: news

Breaking down AGEs: Insight into how lifestyle drives ER-positive breast cancer
(Medical University of South Carolina) Consumption of processed foods high in sugar and fat increase levels of advanced glycation end products (AGEs). Medical University of South Carolina researchers report that AGE levels are higher in patients with estrogen receptor (ER)-positive than ER-negative breast cancer. Addition of AGEs caused breast cancer cells, whose growth had previously been controlled by tamoxifen, to begin to grow again. This suggests that patients with high AGEs may be less likely to respond to tamoxifen treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 27, 2018 Category: Cancer & Oncology Source Type: news

Medication Beliefs Affect Uptake of Preventive Tx for Breast Cancer
Uptake of preventive therapy low among those with strong concerns about tamoxifen, meds in general (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 14, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Medication Beliefs Affect Uptake of Preventive Therapy for Breast Cancer
FRIDAY, Dec. 14, 2018 -- Beliefs about medication are associated with uptake of tamoxifen as a preventive therapy among women at increased risk for breast cancer, according to a study published online Dec. 2 in Clinical Breast Cancer. Rachael Jane... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2018 Category: Pharmaceuticals Source Type: news

Medication Beliefs Affect Uptake of Preventive Tx for Breast Cancer
FRIDAY, Dec. 14, 2018 -- Beliefs about medication are associated with uptake of tamoxifen as a preventive therapy among women at increased risk for breast cancer, according to a study published online Dec. 2 in Clinical Breast Cancer. Rachael Jane... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2018 Category: Pharmaceuticals Source Type: news

Are male doctors too complacent about the cancer pill many women say is ruining their lives?  
Tamoxifen is a daily pill taken by about 550,000 British breast cancer survivors. It can slash their risk of recurrence after treatment by up to 45 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2018 Category: Consumer Health News Source Type: news

Are male doctors too complacent about the cancer pill many women say is ruining their lives? 
Tamoxifen is a daily pill taken by about 550,000 British breast cancer survivors. It can slash their risk of recurrence after treatment by up to 45 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2018 Category: Consumer Health News Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
Title: Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's ReturnCategory: Health NewsCreated: 12/6/2018 12:00:00 AMLast Editorial Review: 12/7/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 7, 2018 Category: Cancer & Oncology Source Type: news

Low-Dose Tamoxifen Feasible Option in Breast Cancer
(MedPage Today) -- Women appear to prevent recurrence in early stage cancers with 5 mg dosing (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 6, 2018 Category: Surgery Source Type: news

Can Low-Dose Tamoxifen Prevent Recurrences With Reduced Toxicity?
The TAM01 trial looked at whether a 5-mg/day dose of tamoxifen was effective in patients with breast intraepithelial neoplasia, or if the 20-mg/day dose was still the best option. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Lower-Dose Tamoxifen Works As Well As High-Dose
New research shows that a lower dose of the hormone therapy Tamoxifen is as effective as the higher dose treatment in helping to prevent breast cancer from returning and guarding against new cancers in women who had high-risk breast tissue. (Source: WebMD Health)
Source: WebMD Health - December 6, 2018 Category: Consumer Health News Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer ’ s Return
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 6, 2018 Category: Cancer & Oncology Tags: Endocrinology, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
THURSDAY, Dec. 6, 2018 -- Tamoxifen is considered a vital weapon in the fight against breast cancer, but many women who have to take the drug struggle with its significant side effects. Now, new research shows that a lower dose of the hormone... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 6, 2018 Category: General Medicine Source Type: news

SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz
THURSDAY, Dec. 6, 2018 -- Tamoxifen at a dose of 5 mg/day is associated with a reduced risk for recurrence for women with hormone-sensitive breast intraepithelial neoplasia, according to a study presented at the annual San Antonio Breast Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2018 Category: Pharmaceuticals Source Type: news

Low-dose tamoxifen reduced recurrence and new disease for patients with DCIS, LCIS, and ADH
(American Association for Cancer Research) Treatment with a low dose of tamoxifen (5 mg per day) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a diagnosis of breast intraepithelial neoplasia compared with placebo, and it did not cause more serious adverse events, according to data from the randomized, phase III TAM-01 clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Adding Metformin to Tamoxifen to Protect the Endometrium Adding Metformin to Tamoxifen to Protect the Endometrium
Might the addition of metformin help mitigate the endometrial effects of tamoxifen therapy?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

A molecule for fighting muscular paralysis
(Universit é de Gen è ve) Myotubular myopathy is a severe genetic disease that leads to muscle paralysis. Although no treatment currently exists, researchers from the UNIGE-with the University of Strasbourg,- have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Since the molecule -- known as tamoxifen -- is already used for breast cancer, the researchers hope to soon set up a clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2018 Category: International Medicine & Public Health Source Type: news

This Combo Improves Outcomes Over Tamoxifen in Early Breast Cancer
New drug combo offers improved disease-free survival in patients with hormone receptor (HR)-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

RT Add-On Boosts Outcomes in'Low-Risk' DCIS Breast Ca
(MedPage Today) -- Highest benefit seen in patients who also used tamoxifen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 22, 2018 Category: Hematology Source Type: news